Search Results for: HSP90AA1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CACYBP calcyclin binding protein
CALM1 calmodulin 1
  • CaMK IV-mediated phosphorylation of CREB
  • CaMK IV-mediated phosphorylation of CREB
  • Calmodulin induced events
  • Cam-PDE 1 activation
  • CaM pathway
  • Platelet degranulation
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • PKA activation
  • DARPP-32 events
  • Synthesis of IP3 and IP4 in the cytosol
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • eNOS activation
  • Transcriptional activation of mitochondrial biogenesis
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Stimuli-sensing channels
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Ca2+ pathway
  • Reduction of cytosolic Ca++ levels
  • Sodium/Calcium exchangers
  • Unblocking of NMDA receptors, glutamate binding and activation
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • Ras activation upon Ca2+ influx through NMDA receptor
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Activation of Ca-permeable Kainate Receptor
  • Uptake and function of anthrax toxins
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • Phase 0 - rapid depolarisation
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • CLEC7A (Dectin-1) induces NFAT activation
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • RAF/MAP kinase cascade
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Protein methylation
  • Extra-nuclear estrogen signaling
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Ion transport by P-type ATPases
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Activation of RAC1 downstream of NMDARs
  • Activation of RAC1 downstream of NMDARs
  • Activation of AMPK downstream of NMDARs
  • Long-term potentiation
  • Long-term potentiation
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Chlorpromazine
  • Cinchocaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • Deacetoxyvinzolidine
  • tert-butanol
  • Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • Myristic acid
  • Calcium citrate
  • Calcium citrate
  • Calcium citrate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium levulinate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
CDC37L1 cell division cycle 37 like 1
  • Platelet degranulation
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
CDK5R1 cyclin dependent kinase 5 regulatory subunit 1
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Regulation of TP53 Activity through Phosphorylation
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • Activated NTRK2 signals through CDK5
  • Indirubin-3'-monoxime
  • 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Bladder cancer
  • Type II diabetes mellitus
  • Pancreatic cancer
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Chronic myeloid leukemia (CML)
  • Oral cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Glioma
  • Osteosarcoma
  • Squamous cell carcinoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Malignant islet cell carcinoma
  • Laryngeal cancer
  • Hepatocellular carcinoma
  • Esophageal cancer
  • Malignant melanoma
CERS2 ceramide synthase 2
  • Sphingolipid de novo biosynthesis
CFTR CF transmembrane conductance regulator
  • ABC-family proteins mediated transport
  • RHO GTPases regulate CFTR trafficking
  • Defective CFTR causes cystic fibrosis
  • Ub-specific processing proteases
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Aggrephagy
  • Aggrephagy
  • ATP
  • Bumetanide
  • Glyburide
  • Ibuprofen
  • Colforsin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Dexfosfoserine
  • Crofelemer
  • Lonidamine
  • Ivacaftor
  • Dexibuprofen
  • Lumacaftor
  • Tezacaftor
  • Elexacaftor
  • Cystic fibrosis (CF)
  • Hereditary pancreatitis; Hereditary chronic pancreatitis
  • Congenital bilateral absence of vas deferens
CHEK1 checkpoint kinase 1
  • Signaling by SCF-KIT
  • Activation of ATR in response to replication stress
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Transcriptional Regulation by E2F6
  • XL844
  • Enzastaurin
  • CHIR-124
  • N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE
  • 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID
  • (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL
  • 2-(cyclohexylamino)benzoic acid
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE
  • (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE
  • (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL
  • 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA
  • (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE
  • 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE
  • 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA
  • 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID
  • 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL
  • (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL
  • (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL
  • N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
  • (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC
  • 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE
  • 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE
  • 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL
  • 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL
  • REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
  • 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine
  • N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE
  • 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE
  • [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone
  • 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol
  • 6-MORPHOLIN-4-YL-9H-PURINE
  • 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE
  • Fostamatinib
CHORDC1 cysteine and histidine rich domain containing 1
CHUK component of inhibitor of nuclear factor kappa B kinase complex
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Aminosalicylic acid
  • Mesalazine
  • Sulfasalazine
  • Acetylcysteine
  • Cocoon syndrome
CKS1B CDC28 protein kinase regulatory subunit 1B
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin D associated events in G1
  • Fluoxetine
  • 2,8-bis[oxido(oxo)vanadio]-1,1,1,3,5,5,7,7,9,9,9-undecaoxopentavanadoxane-2,8-diium
CKS2 CDC28 protein kinase regulatory subunit 2
CRNKL1 crooked neck pre-mRNA splicing factor 1
  • mRNA Splicing - Major Pathway
CSNK2A1 casein kinase 2 alpha 1
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • ATP
  • (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • Emodin
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • Dichlororibofuranosylbenzimidazole
  • Quinalizarin
  • Ellagic acid
  • Fostamatinib
CSNK2A2 casein kinase 2 alpha 2
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • [1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid
  • Fostamatinib
DAP3 death associated protein 3
  • Mitochondrial translation initiation
  • Mitochondrial translation elongation
  • Mitochondrial translation elongation
  • Mitochondrial translation termination
DNAJC7 DnaJ heat shock protein family (Hsp40) member C7
  • Regulation of HSF1-mediated heat shock response
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer

Page 2 out of 9 pages